Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Common Equity (2016 - 2025)

Apyx Medical's Common Equity history spans 16 years, with the latest figure at $14.5 million for Q4 2025.

  • For Q4 2025, Common Equity rose 2.32% year-over-year to $14.5 million; the TTM value through Dec 2025 reached $14.5 million, up 2.32%, while the annual FY2025 figure was $14.5 million, 2.32% up from the prior year.
  • Common Equity reached $14.5 million in Q4 2025 per APYX's latest filing, up from $5.8 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $60.2 million in Q1 2021 to a low of $5.8 million in Q3 2025.
  • Average Common Equity over 5 years is $31.8 million, with a median of $34.9 million recorded in 2023.
  • Peak YoY movement for Common Equity: plummeted 66.66% in 2024, then increased 2.32% in 2025.
  • A 5-year view of Common Equity shows it stood at $54.0 million in 2021, then plummeted by 30.02% to $37.8 million in 2022, then dropped by 28.76% to $26.9 million in 2023, then plummeted by 47.22% to $14.2 million in 2024, then grew by 2.32% to $14.5 million in 2025.
  • Per Business Quant, the three most recent readings for APYX's Common Equity are $14.5 million (Q4 2025), $5.8 million (Q3 2025), and $7.5 million (Q2 2025).